System and upgrades awaiting U.S. FDA clearance
DUBAI-China-based global healthcare company EDAN Instruments, Inc., unveiled its next-generation diagnostic ultrasound system Acclarix LX9 during Arab Health 2020.
The Acclarix LX9 system is currently awaiting 510(k) clearance from the U.S. Food and Drug Administration.
With Acclarix LX9, EDAN is adding artificial intelligence (AI) technologies to its existing ultrasound family. New features include eOB, eLV, eFollicle, eVolFlow, and eNT, all of which, according to Alice Bai, EDAN’s ultrasound clinical application manager, are designed to optimize workloads for sonographers in a various departments, such as obstetrics, gynecology, cardiology, and general surgery.
In addition to the additional AI features, LX9 also offers a 21.5-inch, high resolution LCD screen equipped with a new EIS+ platform that improves image quality. The integrated user interface can also be rotated 180 degrees.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.